IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex

Stopped early

Conditions studied: Primary Insulin-like Growth Factor-1 Deficiency

In brief

This project is a retrospective (beginning January 2006) and prospective patient registry program sponsored by Ipsen (formerly Tercica, Inc.). In collaboration with participating health care practitioners, the patient registry program is an observational study monitoring the long-term safety of patients treated with Increlex® (mecasermin \[rDNA origin\] injection). The IGFD (Increlex® Growth Forum Database) Registry is intended primarily to monitor the safety and efficacy of Increlex replacement therapy in children with growth failure.

Key facts

Study ID

NCT00747604

Run by

Ipsen

People needed

1378

Starts

2006-06-01

Expected to finish

2014-05-01

Last updated by the study team

2020-11-06

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Parents or legally authorized representatives must give signed informed consent before any Registry-related activities are conducted. Assent from the subject should also be obtained where appropriate.
• Patients receiving Increlex® by a qualified practitioner may be enrolled

Where it is running

• Ipsen Central Contact — Basking Ridge, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.